You are here

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

Last updated on February 28, 2019

FOR MORE INFORMATION
Study Location
Alta Bates Summit Comprehensive Cancer Center
Berkeley, California, 94704 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hepatocellular Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Locally advanced or metastatic HCC

- Failure of one prior antiangiogenic therapy including sorafenib, bevacizumab and
brivanib.

- Child-Pugh Class A or B (score 7 only) disease.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prior treatment of advanced HCC with more than one prior first-line systemic therapy.

- Any prior local therapy within 2 weeks of starting the study treatment.

- Presence of hepatic encephalopathy and/or clinically relevant ascites.

- Presence of main portal vein invasion by HCC.

NCT01210495
Pfizer
Completed
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now